dextroamphetamine has been researched along with Sensitivity and Specificity in 20 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " The method was successfully applied to pharmacokinetic study of the QAAMC in beagle dogs." | 1.34 | Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study. ( Chen, Y; Fan, G; Lin, M; Wang, C; Wu, Y; Zhao, W, 2007) |
| "Phenmetrazine is a central nervous system stimulant currently used as an anorectic agent." | 1.30 | A convenient derivatization method for gas chromatography/mass spectrometric determination of phenmetrazine in urine using 2,2,2-trichloroethyl chloroformate. ( Dasgupta, A; Handler, MS; Nine, JS, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (35.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J | 1 |
| Zhang, L | 2 |
| Cheng, X | 1 |
| Shen, B | 1 |
| Qing, C | 1 |
| Fan, G | 2 |
| Martin, PT | 1 |
| Corcoran, M | 1 |
| Zhang, P | 1 |
| Katic, A | 1 |
| Clarke, AR | 1 |
| Barry, RJ | 1 |
| Baker, IE | 1 |
| McCarthy, R | 1 |
| Selikowitz, M | 1 |
| Isiten, HN | 1 |
| Cebi, M | 1 |
| Sutcubasi Kaya, B | 1 |
| Metin, B | 1 |
| Tarhan, N | 1 |
| Sevak, RJ | 1 |
| Stoops, WW | 1 |
| Hays, LR | 1 |
| Rush, CR | 1 |
| Fujiki, N | 1 |
| Cheng, T | 1 |
| Yoshino, F | 1 |
| Nishino, S | 1 |
| Cesari, N | 1 |
| Fontana, S | 1 |
| Montanari, D | 1 |
| Braggio, S | 1 |
| Wongwan, S | 1 |
| Sungthong, B | 1 |
| Scriba, GK | 1 |
| Luzzi, VI | 1 |
| Saunders, AN | 1 |
| Koenig, JW | 1 |
| Turk, J | 1 |
| Lo, SF | 1 |
| Garg, UC | 1 |
| Dietzen, DJ | 1 |
| Silber, BY | 1 |
| Papafotiou, K | 1 |
| Croft, RJ | 1 |
| Stough, CK | 1 |
| Wang, C | 1 |
| Lin, M | 1 |
| Chen, Y | 1 |
| Zhao, W | 1 |
| Wu, Y | 1 |
| Bickel, WK | 1 |
| Oliveto, AH | 1 |
| Kamien, JB | 1 |
| Higgins, ST | 1 |
| Hughes, JR | 1 |
| Slattum, PW | 1 |
| Venitz, J | 1 |
| Barr, WH | 1 |
| Lienau, AK | 1 |
| Kuschinsky, K | 1 |
| Smith, JK | 1 |
| Neill, JC | 1 |
| Costall, B | 1 |
| Chen, YC | 1 |
| Galpern, WR | 1 |
| Brownell, AL | 1 |
| Matthews, RT | 1 |
| Bogdanov, M | 1 |
| Isacson, O | 1 |
| Keltner, JR | 1 |
| Beal, MF | 1 |
| Rosen, BR | 1 |
| Jenkins, BG | 1 |
| Dasgupta, A | 1 |
| Handler, MS | 1 |
| Nine, JS | 1 |
| Markey, P | 1 |
| Mills, KC | 1 |
| Spruill, SE | 1 |
| Kanne, RW | 1 |
| Parkman, KM | 1 |
| Zhang, Y | 1 |
| Vickers, JN | 1 |
| Rodrigues, ST | 1 |
| Brown, LN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I, Randomized, Double Blind, Three-Period Crossover, Estimation Study Using Lisdexamfetamine Dimesylate, Immediate Release Mixed Amphetamine Salts and Placebo to Evaluate the Utility of a Standardized Computer Battery of Tests in Adults With Atten[NCT01010750] | Phase 1 | 18 participants (Actual) | Interventional | 2010-01-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Consists of 12 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 * (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50. (NCT01010750)
Timeframe: 2 and 14 hours post-dose on Day 7
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| 2 hours post-dose | 14 hours post-dose | |
| LDX 50 mg | 64.82 | 66.56 |
| MAS-IR 20 mg | 63.90 | 63.09 |
| Placebo | 64.59 | 64.85 |
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 * (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50. (NCT01010750)
Timeframe: 2 and 14 hours post-dose on Day 7
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| 2 hours post-dose | 14 hours post-dose | |
| LDX 50 mg | 64.21 | 65.08 |
| MAS-IR 20 mg | 63.62 | 63.41 |
| Placebo | 63.28 | 65.74 |
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 * (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50. (NCT01010750)
Timeframe: 2 and 14 hours post-dose on Day 7
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| 2 hours post-dose | 14 hours post-dose | |
| LDX 50 mg | 55.46 | 57.82 |
| MAS-IR 20 mg | 54.58 | 51.53 |
| Placebo | 54.66 | 55.78 |
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 * (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50. (NCT01010750)
Timeframe: 2 and 14 hours post-dose on Day 7
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| 2 hours post-dose | 14 hours post-dose | |
| LDX 50 mg | 58.71 | 59.68 |
| MAS-IR 20 mg | 59.78 | 59.54 |
| Placebo | 58.40 | 59.68 |
Consists of 5 items with each item rated on a scale of 0-3 (not at all, just a little, pretty much, very much). The T-score is then calculated as: T = 50 + 10 * (raw score - mean)/Standard Deviation. The average score is 50. Scores below 50 are better than scores above 50. (NCT01010750)
Timeframe: 2 and 14 hours post-dose on Day 7
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| 2 hours post-dose | 14 hours post-dose | |
| LDX 50 mg | 66.16 | 65.78 |
| MAS-IR 20 mg | 63.39 | 64.45 |
| Placebo | 64.92 | 66.33 |
The Power of Attention score reflects the ability to focus attention, and is calculated as the sum of the reaction time, measured in milliseconds, from 3 attention tests (Simple Reaction Time, Choice Reaction Time, and Digit Vigilance Speed). Faster performance (lower times) reflects more intense concentration. A decrease in the Power of Attention score indicates improvement. (NCT01010750)
Timeframe: pre-dose and at 1, 2, 3, 4, 5, 8, 12, 14 and 16 hours post-dose on Day 7
| Intervention | milliseconds (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| half an hour prior to dosing | 1 hour post-dose | 2 hours post-dose | 3 hours post-dose | 4 hours post-dose | 5 hours post-dose | 8 hours post-dose | 12 hours post-dose | 14 hours post-dose | 16 hours post-dose | |
| LDX 50 mg | 1260.7 | 1244.6 | 1315.5 | 1219.1 | 1225.9 | 1179.6 | 1212.0 | 1232.4 | 1199.3 | 1202.6 |
| MAS-IR 20 mg | 1324.1 | 1307.4 | 1255.0 | 1229.6 | 1236.5 | 1251.4 | 1259.3 | 1239.3 | 1270.1 | 1255.9 |
| Placebo | 1272.8 | 1253.1 | 1296.2 | 1301.0 | 1275.4 | 1330.3 | 1304.5 | 1262.1 | 1270.5 | 1270.3 |
6 trials available for dextroamphetamine and Sensitivity and Specificity
| Article | Year |
|---|---|
Randomized, double-blind, placebo-controlled, crossover study of the effects of lisdexamfetamine dimesylate and mixed amphetamine salts on cognition throughout the day in adults with attention-deficit/hyperactivity disorder.
Topics: Adult; Amphetamines; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulant | 2014 |
An Investigation of Stimulant Effects on the EEG of Children With Attention-Deficit/Hyperactivity Disorder.
Topics: Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Dext | 2017 |
An evaluation of the sensitivity of the standardised field sobriety tests to detect the presence of amphetamine.
Topics: Accidents, Traffic; Adult; Alcoholic Intoxication; Amphetamine-Related Disorders; Dextroamphetamine; | 2005 |
A novel-response procedure enhances the selectivity and sensitivity of a triazolam discrimination in humans.
Topics: Adolescent; Adult; Dextroamphetamine; Discrimination, Psychological; Dose-Response Relationship, Dru | 1993 |
Comparison of methods for the assessment of central nervous system stimulant response after dextroamphetamine administration to healthy male volunteers.
Topics: Adult; Affect; Blood Pressure; Central Nervous System Stimulants; Cross-Over Studies; Dextroamphetam | 1996 |
The influence of stimulants, sedatives, and fatigue on tunnel vision: risk factors for driving and piloting.
Topics: Alcohol Drinking; Alprazolam; Analysis of Variance; Automobile Driving; Aviation; Central Nervous Sy | 2001 |
14 other studies available for dextroamphetamine and Sensitivity and Specificity
| Article | Year |
|---|---|
Determination of d-amphetamine and diphenhydramine in beagle dog plasma by a 96-well formatted liquid-liquid extraction and capillary zone electrophoresis with field-amplified sample stacking.
Topics: Animals; Calibration; Capsules; Chromatography, High Pressure Liquid; Dextroamphetamine; Diphenhydra | 2018 |
Medication Effects on EEG Biomarkers in Attention-Deficit/Hyperactivity Disorder.
Topics: Adolescent; Antidepressive Agents; Attention Deficit Disorder with Hyperactivity; Biomarkers; Brain | 2017 |
Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans.
Topics: Anti-Anxiety Agents; Central Nervous System Stimulants; Dextroamphetamine; Diastole; Discrimination, | 2009 |
Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Tricyclic; Ataxin-3; Benzhydryl Compounds; Cen | 2009 |
Development and validation of a high-throughput method for the quantitative analysis of D-amphetamine in rat blood using liquid chromatography/MS3 on a hybrid triple quadrupole-linear ion trap mass spectrometer and its application to a pharmacokinetic stu
Topics: Animals; Chromatography, Liquid; Dextroamphetamine; Drug Stability; Male; Rats; Rats, Sprague-Dawley | 2010 |
CE assay for simultaneous determination of charged and neutral impurities in dexamphetamine sulfate using a dual CD system.
Topics: Acetone; Amphetamine; beta-Cyclodextrins; Calibration; Dextroamphetamine; Drug Contamination; Electr | 2010 |
Analytic performance of immunoassays for drugs of abuse below established cutoff values.
Topics: Cocaine; Dextroamphetamine; Dronabinol; Gas Chromatography-Mass Spectrometry; Humans; Immunoassay; M | 2004 |
Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of D-amphetamine and diphenhydramine in beagle dog plasma and its application to a pharmacokinetic study.
Topics: Animals; Chromatography, High Pressure Liquid; Dextroamphetamine; Diphenhydramine; Dogs; Reference S | 2007 |
Sensitization phenomena after repeated administration of cocaine or D-amphetamine in rats: associative and non-associative mechanisms and the role of dopamine in the striatum.
Topics: Animals; Cocaine; Dextroamphetamine; Dopamine; Locomotion; Male; Rats; Rats, Wistar; Sensitivity and | 1997 |
Post-weaning housing conditions influence the behavioural effects of cocaine and d-amphetamine.
Topics: Animals; Behavior, Animal; Cocaine; Dextroamphetamine; Female; Locomotion; Rats; Sensitivity and Spe | 1997 |
Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data.
Topics: Adrenergic Agents; Animals; Behavior, Animal; Brain; Cocaine; Dextroamphetamine; Dopamine; Dopamine | 1997 |
A convenient derivatization method for gas chromatography/mass spectrometric determination of phenmetrazine in urine using 2,2,2-trichloroethyl chloroformate.
Topics: Appetite Depressants; Cross Reactions; Dextroamphetamine; Forensic Medicine; Gas Chromatography-Mass | 1998 |
Is it truly random?
Topics: Attention Deficit Disorder with Hyperactivity; Australia; Central Nervous System Stimulants; Dextroa | 1999 |
Gaze pursuit and arm control of adolescent males diagnosed with attention deficit hyperactivity disorder (ADHD) and normal controls: evidence of a dissociation in processing visual information of short and long duration.
Topics: Adolescent; Analysis of Variance; Arm; Attention Deficit Disorder with Hyperactivity; Case-Control S | 2002 |